echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > 4 products have entered the clinic Eisai still decided to close H3 Biomedicine

    4 products have entered the clinic Eisai still decided to close H3 Biomedicine

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    In recent years, cancer has become the "number one killer" of human health, and the demand for medication is expanding

    But the field of oncology is also the most competitive field in the future, and the speed of drug update iteration may exceed the perception
    of many people.

    Eisai announced its resolution to restructure its global structure from its previous business group structure to a new R&B, Deep Human Biology Learning

    A few days later, Eisai decided to permanently shut down its oncology department, H3 Biomedicine, with an estimated layoff of 88, 79 of whom will be laid off
    by September 15.

    4 products have entered the clinic

    4 products have entered the clinic 4 products have entered the clinic

    Eisai still decided to shut down H3 Biomedicine

    Eisai still decided to close H3 BiomedicineEisai still decided to close H3 Biomedicine

    Founded in 2010, H3 Biomedicine focuses on discovering and developing precision cancer treatments using its integrated data science, human biology and precision chemistry discovery engine

    At present, 4 products have entered the clinical development stage

    H3 Biomedicine product line

    Source: H3 Biomedicine

    Last August, H3 also hired Ross Pettit, former senior vice president of global development operations at BeiGene, as vice president of
    business operations.

    On July 15, 2022, Eisai announced a new organizational structure, DHBL (Deep Human Biology Learning), which is scheduled to be launched
    on October 1, 2022.
    Previously, the Neurology Group, Oncology Group, Drug Development Center, and HC Data Creation Center will be dissolved
    The closure of H3 Biomedicine is part of
    that huge plan.

    Eisai explained that under the discovery and development of new DHBL drugs, diseases will be regarded as disease continuums, and genetic information, pathophysiological information and clinical information related to the root causes of diseases will be comprehensively analyzed
    Eisai will use AI and other technologies to discover next-generation drugs
    more efficiently and innovatively through deeper human biological learning, information based on patients' biomarkers and medical images.

    On the other hand, Eisai said that Alzheimer's disease and related brain disease modification therapy (DMT) related research and development, supervision, medical treatment, value, access, marketing and alliance management functions, of which the next generation of Alzheimer's disease treatment drug lecanemab, is its most important project

    Bet on the field of neurological diseases

    Bets on the field of neurological diseases and the field of neurological diseases with all your might

    Can Eisai turn over?

    Can Eisai turn over? Can Eisai turn over?

    Eisai Pharmaceutical, headquartered in Tokyo, Japan, is one of
    Japan's top five pharmaceutical giants.

    As early as 1996, Eisai launched the classic treatment drug of Alzheimer's disease Doneprazine hydrochloride, and joined hands with the two giants of Pfizer and Johnson & Johnson to make the drug an "explosive product"
    For decades thereafter, Eisai has been betting heavily on CNS drug development

    According to its fiscal 2021 annual report, two of its four highest-selling major products belong to the field of neurological diseases – Fycompa and Dayvigo, with sales of 31.
    9 billion yen (about 1.
    57 billion yuan) and 16.
    4 billion yen (about 809 million yuan)

    Eisai commercialized and marketed products

    Source: Eisai

    More than twenty years after the introduction of donepezi, Eisai launched Aduhelm last year to treat early-stage Alzheimer's disease
    However, this time Eisai was not so lucky, and Aduhelm's approval was controversial and did not achieve the expected sales

    However, the Aduhelm storm did not affect the research and development
    of Lecanemab, another Alzheimer's disease therapy cooperated by Bojian and Eisei.

    A few days ago, Eisai and Bo Jian announced that the US FDA has granted them the Lecanemab priority review qualification for the in-research treatment of Alzheimer's disease, and the PDUFA date is January 6, 2023
    The drug was recognized as a breakthrough therapy by the FDA in June last year and was highly anticipated
    by Eisai.

    Lecanemab, similar to Aduhelm's principle of action, is a humanized monoclonal antibody
    for the treatment of Alzheimer's disease (AD).
    Lecanemab selectively binds to neutralize and eliminate soluble, toxic Aβ aggregates (fibrinofibrils) that are thought to accelerate the neurological degeneration process
    of AD.
    Thus, lecanemab may have an effect on the pathologic mechanisms of the disease and delay disease progression

    Lecanemab's biologics license application is based on Lecanemab's clinical, biomarker and safety data from the proof-of-concept Phase IIb clinical trial, the Open Label Extended Study, and the unblinded safety data
    of ongoing Phase III clinical trials.
    Data from phase IIb clinical trials showed that lecanemab reduced amyloid plaque levels in the
    After 18 months of treatment, lecanemab (10 mg/kg every two weeks) reduced brain amyloid levels by an average of 0.
    306 SUVr (baseline value of 1.

    More than 80% of the participants met the amyloid negative criteria
    for visual evaluation of scans.
    At the same time, the reduced levels of amyloid are associated with a slowdown in the clinical decline in multiple cognitive scores
    In addition, the ongoing Phase III clinical treatment of early-stage AD is expected to have primary clinical endpoint data
    available this fall.

    In addition to lecanemab, Eisai also has a number of products in the field of neurological diseases that are also worth paying attention to

    Lemborexant (Dayvigo) is a small molecule orexin receptor antagonist
    independently developed by Eisai.
    The results of two critical phase 3 studies (SUNRISE 2 and SUNRISE 1) in adult patients with insomnia showed a statistically significant advantage
    in both subjective and objective evaluation compared with placebo.
    As a result, Dayvigo was approved by the US FDA in 2019, becoming the first insomnia drug
    to have 12 months of treatment safety data and 6 months of sleep and sleep maintenance efficacy data in key studies.

    Fycompa (Piram Panayne) is a new type of anti-epileptic drug developed by Eisai and is a highly selective, non-competitive AMPA receptor antagonist
    At present, pyrampanaj has been approved for marketing in more than 70 countries and regions, including Japan, the United States, China, and other countries in Europe and Asia, as an adjunct to
    partial seizures (with or without secondary generalized seizures) in patients with epilepsy aged 12 years and older.
    In addition, the globally approved indications for pirampanaj include adjuvant therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older, monotherapy and adjunctive treatment of partial seizures (with or without secondary generalized seizures)
    in patients with epilepsy 4 years and older.
    Eisai is also conducting a phase III clinical study (Study 338) worldwide with the intention of using the drug to treat seizures
    associated with Lennox-Gastaut syndrome.
    In addition, the development of Eisai injection preparations is also underway

    Lorcaserin (Belviq) is a selective serotonin serotonin 2C (5-HT2c) receptor agonist
    Originally developed by the American pharmaceutical company Arena, it was approved by the FDA in 2012 for adult obese or overweight patients with a BMI ≥ 27kg/m2, and later Eisai signed an exclusive license agreement with Arena to obtain the commercialization rights
    of Locaserin in most countries and regions around the world.
    However, in 2020, the FDA asked for the discontinuation of lorcaserin, as clinical trials showed an increase in cancer incidence
    At the same time, however, Lostoryrin has made progress
    in treating chronic severe epilepsy (Dravet syndrome) in children.
    A Phase 3 study of the indication for Dravet syndrome is currently underway and the FDA has granted it orphan drug qualification
    for this indication.



    In recent years, the emergence of new technologies such as immunotherapy has made great progress in anti-tumor treatment, and various new drugs have appeared in the field
    However, the problems of high risk and fierce competition in the research and development of new anti-tumor drugs cannot be ignored

    At this year's ASCO conference, Pfizer's world-first CDK4/6 inhibitor pipercille clinical data is not ideal, and it will be at a disadvantage when facing Novartis's Regislil and Lilly's
    Abecilique in the future when competing globally.
    The failure of Roche's TIGIT has cast a shadow over a
    number of new drugs targeting TIGIT.
    The Enhertu of the First Third Republic and AstraZeneca, because of the excellent clinical data, may profoundly affect the treatment of breast cancer, and at the same time may cause a very fatal blow
    to the development of subsequent drugs and the drugs designed as "templates" of the previous generation of ADC drugs.

    The oncology field has long been a competition in the Red Sea, with high risks and uncertain life cycles, and may not be the best choice
    for "endogenous growth" companies.

    For some areas that are slowly updated, such as the Alzheimer's Track, in recent years, in addition to Aduhelm of Eisai and the domestic nine phase one, new drugs that can count the names and are recognized by the market have basically disappeared
    With its deep accumulation in the field of neurological diseases, Eisai may really be able to break the deadlock of new drugs for Alzheimer's disease and achieve new glory

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.